Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 13/20 | 0.51 |
| ▸ | GIPR | P48546 | 6/20 | 0.51 |
| ▸ | GLP1R | P43220 | 2/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.47 |
| ▸ | SERPINE1 | P05121 | 2/20 | 0.44 |
| ▸ | PTGES | O14684 | 3/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.44 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2655070 | 0.95 | GCGR (0.53) | GCGRGIPRGLP1RMAPK14ROCK2 | |
| SCHEMBL2659173 | 0.93 | GCGR (0.59) | GCGRGIPRGLP1RSERPINE1 | |
| SCHEMBL2654344 | 0.92 | GCGR (0.47) | GCGRGIPRGLP1RMAPK14ROCK2 | |
| SCHEMBL2654715 | 0.92 | GCGR (0.55) | GCGRGIPRGLP1RMAPK14ROCK2 | |
| SCHEMBL2659962 | 0.91 | GCGR (0.58) | GCGRGIPRGLP1RMAPK14ROCK2 | |
| SCHEMBL2666358 | 0.89 | GCGR (0.51) | GCGRGIPRGLP1RMAPK14ROCK2 | |
| SCHEMBL2654511 | 0.88 | GCGR (0.62) | GCGRGIPRGLP1RMAPK14 | |
| SCHEMBL2652571 | 0.87 | GCGR (0.53) | GCGRGIPRGLP1RMAPK14ROCK2 | |
| SCHEMBL2654534 | 0.87 | GCGR (0.49) | GCGRGIPRGLP1RMAPK14ROCK2 | |
| SCHEMBL2654983 | 0.87 | GCGR (0.60) | GCGRGIPRGLP1RMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040152750-A1 | Novel glucagon antagonists | NOVO NORDISK A/S (DK) | 2004-08-05 | — | — | US | disclosed |
| WO-2004056763-A2 | NOVEL GLUCAGON ANTAGONISTS | NOVO NORDISK A/S (DK) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004056763-A2 | NOVEL GLUCAGON ANTAGONISTS | NOVO NORDISK A/S (DK) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152750-A1 | Novel glucagon antagonists | GLP1R, GCGR, GIPR | GCGR 2/4885GIPR 3/4885GLP1R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.